Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | VCP | P55072 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290719 | 1.00 | AKR1C3 (0.62) | AKR1C3AKR1C2MAOBMAOAVCP | |
| SCHEMBL2571095 | 0.86 | AKR1C3 (0.67) | AKR1C3AKR1C2MAOBMAOAKDM4E | |
| SCHEMBL2571093 | 0.86 | AKR1C3 (0.67) | AKR1C3AKR1C2MAOBMAOAKDM4E | |
| SCHEMBL8149850 | 0.84 | MAOB (0.57) | AKR1C3AKR1C2MAOBMAOAVCP | |
| SCHEMBL17157614 | 0.84 | MAOB (0.59) | AKR1C3AKR1C2MAOBMAOAVCP | |
| SCHEMBL17157612 | 0.84 | MAOB (0.59) | AKR1C3AKR1C2MAOBMAOAVCP | |
| SCHEMBL8149848 | 0.84 | MAOB (0.57) | AKR1C3AKR1C2MAOBMAOAVCP | |
| SCHEMBL407484 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL407485 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 | |
| SCHEMBL29389045 | 0.83 | KDM4E (0.58) | AKR1C3AKR1C2KDM4EHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-20240300968-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | UNIV MANCHESTER (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-4377300-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | The University of Manchester (GB) | 2024-06-05 | — | — | EP | disclosed |
| CN-117730077-A | 6-substituted naphthalene-1, 3-disulfonic acid derivatives as modulators of extracellular nicotinamide ribophosphate transferase (ENAMPT) for the treatment of, for example, diabetes | 曼彻斯特大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117264935-A | Phenylalanine ammonia lyase mutant and application thereof | 中国科学院成都生物研究所 | 2023-12-22 | — | — | CN | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023007147-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023007147-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2001096297-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-RE36625-E | Linear and cyclic polymers or oligomers having a photoreactive ethene group | ROLIC AG (CH) | 2000-03-21 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5670498-A | ADENOSINE ANTAGONISTS, TREATMENT OF PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, OSTEOPOROSIS, DEPRESSION, ASTHMA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| EP-0607607-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-09-18 | — | — | EP | disclosed |
| US-5539074-A | LIQUID CRYSTAL POLYMERS ON SILICA FOR LIGHT SENSITIVE ELEMENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0607607-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300968-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | NAPRT, NAMPT, NUDT1 | AKR1C3 945/4885AKR1C2 993/4885MAOB 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.